Overview of the ASCENT Trial and Trodelvy The ASCENT Trial (NCT02574455) is a Phase III study that compares Trodelvy (Sacituzumab Govitecan), a targeted cancer drug, to standard chemotherapy chosen by doctors (TPC). For instance, it focused on patients with metastatic triple-negative breast cancer (mTNBC) who had tried at least two prior treatments. As a result, … Continue reading ASCENT Trial: Trodelvy Boosts Survival in Triple-Negative Breast Cancer